← Leaderboards
Debra Odink
Siteone Therapeutics, Inc.
$3,260,885
Attributed
$6,521,770
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2019–21$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
Funding mix
By agency
NIH$6,521,770 · 2
By mechanism
UG3$5,378,065 · 1
U44$1,143,705 · 1
Top collaborators
- John Vincent Mulcahy3 shared
- John Cureton Hunter2 shared
Most similar at Siteone Therapeutics, Inc.
Same institution · by research overlap
- John Vincent Mulcahy$6,301,912
- Anton Delwig$2,325,019
- John Cureton Hunter$6,388,430
- George Miljanich$601,209
- Sheri Denet Klas$1,802,944
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsProtein IsoformsNeuronsPeripheralPreventProgramsIntravenousLeadNon-Opioid AnalgesicPain ReductionPhase I Clinical TrialsAnalgesicsDrug UsageExhibitsDoseInhibitor/AntagonistIn VivoBaseClinical DevelopmentNonhuman PrimateDesignPainAfferent NeuronsRattus
Grant awards (5)
Discovery of NaV1.7 Inhibitors for the Treatment of Pain$455,622
U44 · FY2021 · NS
Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders$2,440,102
UG3 · FY2020 · DA
Discovery of NaV1.7 Inhibitors for the Treatment of Pain$461,907
U44 · FY2020 · NS
Development of a Potent and Highly Selective NaV1.7 Inhibitor for the Treatment of Acute Pain with the Goal of Reducing Opioid Use and Preventing Opioid Use Disorders$2,937,963
UG3 · FY2019 · DA
Discovery of NaV1.7 Inhibitors for the Treatment of Pain$226,176
U44 · FY2019 · NS